Candel Therapeutics Inc

NASDAQ:CADL   3:59:55 PM EDT
3.43
-0.08 (-2.28%)
Earnings Announcements

Candel Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/12/2022 12:35 GMT
Candel Therapeutics Inc (CADL) - Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights.
Cash and Cash Equivalents As of March 31, 2022 Were $94.3 Million Compared to $82.6 Million As of December 31, 2021.
Cash and Cash Equivalents As of March 31, 2022 Were $94.3 Million.
Expects That Its Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Operations Into Q4 of 2023.
Qtrly Loss per Share $0.03.
Revenue is expected to be $0.01 Million
Adjusted EPS is expected to be -$0.32

Next Quarter Revenue Guidance is expected to be $0.01 Million
Next Quarter EPS Guidance is expected to be -$0.38

More details on our Analysts Page.